Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH(TM) from Centers for Medicare and Medicaid Services

Stock Information for Verrica Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Verrica Pharmaceuticals Inc.

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals Announces that YCANTH(TM) Receives New Chemical Entity Status and Orange Book Listing from the FDA
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.